[go: up one dir, main page]

CL2011001225A1 - Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros. - Google Patents

Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.

Info

Publication number
CL2011001225A1
CL2011001225A1 CL2011001225A CL2011001225A CL2011001225A1 CL 2011001225 A1 CL2011001225 A1 CL 2011001225A1 CL 2011001225 A CL2011001225 A CL 2011001225A CL 2011001225 A CL2011001225 A CL 2011001225A CL 2011001225 A1 CL2011001225 A1 CL 2011001225A1
Authority
CL
Chile
Prior art keywords
propanol
glycerol
ethanol
aqueous solution
fatty acid
Prior art date
Application number
CL2011001225A
Other languages
English (en)
Inventor
Michele Virno
Original Assignee
Lectio Pharmaentwicklungs Und Verwertungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lectio Pharmaentwicklungs Und Verwertungs Gmbh filed Critical Lectio Pharmaentwicklungs Und Verwertungs Gmbh
Publication of CL2011001225A1 publication Critical patent/CL2011001225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación farmacéutica en solución acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidróxido de ácido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilen glicol entre otros.
CL2011001225A 2008-11-28 2011-05-26 Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros. CL2011001225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170177 2008-11-28

Publications (1)

Publication Number Publication Date
CL2011001225A1 true CL2011001225A1 (es) 2011-11-11

Family

ID=40512558

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001225A CL2011001225A1 (es) 2008-11-28 2011-05-26 Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.

Country Status (15)

Country Link
US (1) US20110275717A1 (es)
EP (1) EP2364140A1 (es)
JP (1) JP2012510439A (es)
KR (1) KR20110091862A (es)
CN (1) CN102227211A (es)
AU (1) AU2009319167A1 (es)
BR (1) BRPI0921654A2 (es)
CA (1) CA2742645A1 (es)
CL (1) CL2011001225A1 (es)
EA (1) EA201100863A1 (es)
IL (1) IL212602A0 (es)
MX (1) MX2011005410A (es)
NZ (1) NZ592647A (es)
WO (1) WO2010060798A1 (es)
ZA (1) ZA201103335B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200903135B (en) 2006-10-17 2010-08-25 Nuvo Res Inc Diclofenac gel
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
ITMI20121205A1 (it) 2012-07-11 2014-01-12 Glycores 2000 Srl Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione
EP2872177B1 (en) * 2012-07-12 2017-12-20 Ferring BV Diclofenac formulations
US20140187635A1 (en) 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
CN104274436B (zh) * 2013-07-03 2017-05-10 成都力思特制药股份有限公司 双氯芬酸钠盐酸利多卡因复方药物注射液及其制备方法
KR101524473B1 (ko) * 2014-12-22 2015-06-02 주식회사 한국팜비오 주사제 조성물
KR101654900B1 (ko) * 2016-02-04 2016-09-07 주식회사 한국루베 저독성 화생방 제독제
US20220280463A1 (en) 2019-09-09 2022-09-08 Ftf Pharma Private Limited Pharmaceutical formulations comprising diclofenac
WO2021228804A1 (de) * 2020-05-12 2021-11-18 U. Windmöller Innovation Gmbh & Co. Kg Verfahren zur herstellung von hydroxyfettsäurebasierten polyolen
CN112516081B (zh) * 2020-12-16 2023-03-10 郑州百瑞动物药业有限公司 一种双氯芬酸注射液及其制备方法
EP4112042A1 (en) * 2021-06-30 2023-01-04 GSK Consumer Healthcare SARL Nanoemulsion comprising diclofenac
KR20240164788A (ko) 2022-03-25 2024-11-20 글리코레스 2000 에세.에레.엘레 항염증 및 진통 활성을 갖는 국소 약학적 조성물 및 이의 용도
US20250099369A1 (en) 2023-09-27 2025-03-27 Andros Pharmaceuticals Co., Ltd. Topical delivery compositions comprising non-steroidal anti-inflammatory drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655656B (es) * 1982-10-07 1986-05-15
ES2053161T3 (es) * 1989-09-21 1994-07-16 Ciba Vision Ag Composiciones antimicrobianas.
JP4275751B2 (ja) * 1996-12-27 2009-06-10 久光製薬株式会社 外用組成物
ES2174462T3 (es) * 1997-07-29 2002-11-01 Upjohn Co Formulacion autoestimulante para compuestos lipofilos.
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
EP1812033A4 (en) * 2004-10-06 2009-11-11 Tiltan Pharma Ltd METHOD AND COMPOSITION FOR REINFORCE ANTI-ANGIOGENESIS THERAPY
AU2007270686B2 (en) * 2006-07-07 2011-05-26 Tiltan Pharma Ltd. Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen

Also Published As

Publication number Publication date
JP2012510439A (ja) 2012-05-10
NZ592647A (en) 2013-05-31
US20110275717A1 (en) 2011-11-10
ZA201103335B (en) 2012-01-25
IL212602A0 (en) 2011-07-31
WO2010060798A1 (en) 2010-06-03
KR20110091862A (ko) 2011-08-16
EP2364140A1 (en) 2011-09-14
EA201100863A1 (ru) 2011-12-30
CN102227211A (zh) 2011-10-26
CA2742645A1 (en) 2010-06-03
BRPI0921654A2 (pt) 2016-02-10
MX2011005410A (es) 2011-06-16
AU2009319167A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
CL2009000870A1 (es) Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros.
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
ES2500064T3 (es) Composiciones básicas que comprenden un alcanol y una sal de ácido graso o un glicérido de ácido graso para esterilizar un material
CR20120167A (es) Conjugados de niacina y ácidos grasos y sus usos
PE20090910A1 (es) Composicion topica
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
MX354647B (es) Composicion farmaceutica anticonvulsiva transnasal que comprende un anticonvulsivante escasamente soluble.
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
PE20140255A1 (es) Tableta dispersable en forma oral
AR073901A1 (es) Composicion topica farmaceutica, unguento y cremas que la comprende, y sus usos
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
CO6410282A2 (es) Formulaciones orales sólidas de una pirido-pirimidinona
NO20084478L (no) Konjugerte lipidderivater
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
RU2009128593A (ru) Средства борьбы с паразитами животных